International Stem Cell (ISCO) EBITDA Margin (2010 - 2026)
International Stem Cell (ISCO) posted EBITDA Margin of -0.26% for Q2 2026, down 9.29 percentage points from 9.03% a year earlier.
Powered by 
Analysis
International Stem Cell (ISCO) EBITDA Margin (2010 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, EBITDA Margin at International Stem Cell was 1.09%, down 0.31 percentage points year-over-year; for FY2025, it was -0.53%, down 2.05 percentage points from FY2024.
- Annual EBITDA Margin shows a five-year change of +35.46 percentage points (FY2020 to FY2025).
- In prior years, International Stem Cell's EBITDA Margin was 1.52% in FY2024 (+7.54 pp), -6.02% in FY2023 (-6.45 pp), 0.43% in FY2022 (+23.55 pp) and -23.12% in FY2021 (+12.87 pp).
- Quarterly EBITDA Margin has run from a low of -30.29% in Q3 2021 to a high of 9.03% in Q2 2025 over five years.
- On a year-over-year basis, EBITDA Margin increased in four of the last seven quarters, with an average year-over-year change of +0.93 percentage points.
- The strongest year-over-year quarter for EBITDA Margin in the past five years was Q1 2022, with a gain of 34.23 percentage points; the weakest was Q4 2023, with a drop of 24.55 percentage points.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,134.61 Bn | 1,103.20 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 616.25 Bn | 534.77 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 501.45 Bn | 474.56 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 367.41 Bn | 321.79 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 297.99 Bn | 261.98 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.44 Bn | 235.12 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 235.87 Bn | 191.27 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 190.66 Bn | 164.86 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 169.40 Bn | 116.05 Bn | 10.94 Bn | 39.16% |
| 10 | International Stem Cell | 1.68 Mn | -2.29 Mn | 1.46 Mn | -0.26% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.26% |
| Dec 31, 2025 | -12.02% |
| Sep 30, 2025 | 6.33% |
| Jun 30, 2025 | 9.03% |
| Mar 31, 2025 | -7.52% |
| Dec 31, 2024 | 4.29% |
| Sep 30, 2024 | -1.70% |
| Jun 30, 2024 | 8.54% |
| Mar 31, 2024 | -6.06% |
| Dec 31, 2023 | -19.90% |
| Sep 30, 2023 | -2.53% |
| Jun 30, 2023 | -5.21% |
| Mar 31, 2023 | 2.54% |
| Dec 31, 2022 | 4.65% |
| Sep 30, 2022 | -14.39% |
| Jun 30, 2022 | 4.24% |
| Mar 31, 2022 | 4.01% |
| Dec 31, 2021 | -13.89% |
| Sep 30, 2021 | -30.29% |
| Jun 30, 2021 | -18.66% |
API Access
International Stem Cell EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ISCO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "ISCO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ISCO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();